Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of unusually large options trading activity on Monday. Investors acquired 2,879 call options on the company. This represents an increase of approximately 1,423% compared to the typical daily volume of 189 call options.
Shares of NASDAQ AEZS traded up $0.11 during midday trading on Monday, hitting $0.65. The stock had a trading volume of 22,661,000 shares, compared to its average volume of 11,732,650. The business’s 50 day moving average is $0.41 and its 200-day moving average is $0.44. The company has a market cap of $41.04 million, a P/E ratio of -3.00 and a beta of 2.10. Aeterna Zentaris has a 52 week low of $0.29 and a 52 week high of $1.54.
Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. Aeterna Zentaris had a negative net margin of 369.10% and a negative return on equity of 125.54%. The company had revenue of $0.13 million for the quarter.
An institutional investor recently raised its position in Aeterna Zentaris stock. Morgan Stanley boosted its stake in shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 34.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,123,998 shares of the biopharmaceutical company’s stock after acquiring an additional 286,853 shares during the period. Morgan Stanley owned 1.79% of Aeterna Zentaris worth $395,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.44% of the company’s stock.
About Aeterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
See Also: What is a price target?
Receive News & Ratings for Aeterna Zentaris Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aeterna Zentaris and related companies with MarketBeat.com’s FREE daily email newsletter.